Compare Smith & Nephew plc (SNN) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vertiv Holdings Co — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Vertiv Holdings Co trades at $247.2 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 8.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Vertiv Holdings Co for 39 Days on average.
| SNN | VRT | |
|---|---|---|
Market Cap | $11.10B | $93.83B |
Volume | 1,051,703 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $37.17 | $376.23 |
52-Week Low | $26.42 | $149.83 |
Typical Hold Time | 120 Days | 39 Days |
Enterprise Value | $14.13B | $94.06B |
Dividend Yield | 2.95% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Vertiv (VRT) trades at $246.49, down 2.63% on the day, as technical indicators show bearish momentum with the stock testing support near $242. Fundamentally, the company demonstrates strong profitability with 38% gross margins and 15% net income margins, while recent earnings have consistently beaten expectations. Revenue growth accelerated from $10.2B in 2025 to $11.5B projected for 2026, driven by AI data center demand.
The investment case balances strong analyst support (95% buy ratings with $364.94 price target) against elevated valuation multiples (P/E of 55) and recent legal scrutiny. While AI infrastructure tailwinds provide growth catalysts, the stock faces technical headwinds and needs to maintain its earnings beat streak to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
